Keywords: Shire, FDA labeling, ADHD, Vyvanse, Adderall, Watson, Law suit

Upbeat news for Shire as FDA delays labeling decision on ADHA drugs; firm sues Watson

Article | 11 April 2011

Print This

In what was largely viewed as positive news for Ireland headquartered Shire (LSE: SHP), the Food and Drug Administration has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in